{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:14:37Z","timestamp":1788250477605,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>We examined associations of county- and tract-level Social Vulnerability Index (SVI) with survival and treatment-related outcomes in adults with IDH-wildtype glioblastoma (GBM) or IDH-mutant grade 4 astrocytoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults treated at MD Anderson from 2020 to 2025 with PROACTIVE consent, survival follow-up, and Texas residential data were included. The 2022 CDC\/ATSDR SVI was modeled per 0.1 increase (10 percentile points). Primary Cox models for GBM adjusted for age, sex, performance status, extent of resection, MGMT methylation, insurance, and distance. Proportional hazards were assessed using Grambsch\u2013Therneau tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Cohorts included 398 patients with GBM and 62 with IDH-mutant grade 4 astrocytoma. In GBM, SVI was not associated with survival in county-level analyses (HR per 0.1 increase, 1.00; 95% CI, 0.96\u20131.05;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.920) or Houston-area tract-level analyses (HR, 1.05; 95% CI, 0.98\u20131.13;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.176). In exploratory time-varying analysis, the SVI\u2013mortality association attenuated over follow-up (interaction\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.028). Higher tract-level SVI was associated with greater odds of not undergoing gross-total resection (OR, 1.19; 95% CI, 1.07\u20131.33; q\u2009=\u20090.010) and lower odds of clinical-trial treatment (OR, 0.81; 95% CI, 0.71\u20130.92; q\u2009=\u20090.008). No significant survival association was identified in exploratory astrocytoma analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among patients who reached tertiary neuro-oncology care, primary Cox models did not identify a statistically significant association between SVI and survival. Higher tract-level SVI was associated with less extensive resection and lower odds of clinical-trial treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11060-026-05732-y","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:02:06Z","timestamp":1785405726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Social vulnerability and survival among patients with high-grade glioma treated at a tertiary cancer center"],"prefix":"10.1007","volume":"179","author":[{"given":"Aileen H.","family":"Hsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetna","family":"Wathoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Nassif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Buchold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna H.","family":"McNeill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Hawk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay K.","family":"Puduvalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Kamiya-Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"issue":"Suppl 4","key":"5732_CR1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaf194","volume":"27","author":"M Price","year":"2025","unstructured":"Price M, Ballard CAP, Benedetti JR, Kruchko C, Barnholtz-Sloan JS, Ostrom QT (2025) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2018\u20132022. Neuro Oncol 27(Suppl 4):iv1\u2013iv66. https:\/\/doi.org\/10.1093\/neuonc\/noaf194","journal-title":"Neuro Oncol"},{"key":"5732_CR2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"5732_CR3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G et al (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18:170\u2013186. https:\/\/doi.org\/10.1038\/s41571-020-00447-z","journal-title":"Nat Rev Clin Oncol"},{"key":"5732_CR4","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"5732_CR5","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997\u20131003. https:\/\/doi.org\/10.1056\/NEJMoa043331","journal-title":"N Engl J Med"},{"key":"5732_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamaoncol.2019.6143","volume":"6","author":"AM Molinaro","year":"2020","unstructured":"Molinaro AM, Hervey-Jumper S, Morshed RA, Young JS, Han SJ, Chunduru P et al (2020) Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma. JAMA Oncol 6:495\u2013503. https:\/\/doi.org\/10.1001\/jamaoncol.2019.6143","journal-title":"JAMA Oncol"},{"key":"5732_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/nop\/npy014","volume":"6","author":"EV Dressler","year":"2019","unstructured":"Dressler EV, Liu M, Garcia CR, Dolecek TA, Pittman T, Huang B et al (2019) Patterns and disparities of care in glioblastoma. Neurooncol Pract 6:37\u201346. https:\/\/doi.org\/10.1093\/nop\/npy014","journal-title":"Neurooncol Pract"},{"key":"5732_CR8","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1002\/cncr.34881","volume":"129","author":"D Estevez-Ordonez","year":"2023","unstructured":"Estevez-Ordonez D, Abdelrashid M, Coffee E, Laskay NMB, Atchley TJ, Chkheidze R et al (2023) Racial and socioeconomic disparities in glioblastoma outcomes: a single-center retrospective cohort study. Cancer 129:3010\u20133022. https:\/\/doi.org\/10.1002\/cncr.34881","journal-title":"Cancer"},{"issue":"Suppl 1","key":"5732_CR9","doi-asserted-by":"publisher","first-page":"i11","DOI":"10.1093\/jrr\/rrx103","volume":"59","author":"EL Pollom","year":"2018","unstructured":"Pollom EL, Fujimoto DK, Han SS, Harris JP, Tharin SA, Soltys SG et al (2018) Newly diagnosed glioblastoma: adverse socioeconomic factors correlate with delay in radiotherapy initiation and worse overall survival. J Radiat Res 59(Suppl 1):i11\u2013i18. https:\/\/doi.org\/10.1093\/jrr\/rrx103","journal-title":"J Radiat Res"},{"key":"5732_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3171\/2021.7.JNS211307","volume":"137","author":"A Goyal","year":"2022","unstructured":"Goyal A, Zreik J, Brown DA, Kerezoudis P, Habermann EB, Chaichana KL et al (2022) Disparities in access to surgery for glioblastoma multiforme at high-volume Commission on Cancer-accredited hospitals in the United States. J Neurosurg 137:32\u201341. https:\/\/doi.org\/10.3171\/2021.7.JNS211307","journal-title":"J Neurosurg"},{"key":"5732_CR11","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3171\/2018.10.JNS182247","volume":"132","author":"P Zhu","year":"2020","unstructured":"Zhu P, Du XL, Zhu JJ, Esquenazi Y (2020) Improved survival of glioblastoma patients treated at academic and high-volume facilities: a hospital-based study from the National Cancer Database. J Neurosurg 132:491\u2013502. https:\/\/doi.org\/10.3171\/2018.10.JNS182247","journal-title":"J Neurosurg"},{"key":"5732_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jocn.2019.04.028","volume":"68","author":"S Aulakh","year":"2019","unstructured":"Aulakh S, DeDeo MR, Free J, Rosenfeld SS, Qui\u00f1ones-Hinojosa A, Paulus A et al (2019) Survival trends in glioblastoma and association with treating facility volume. J Clin Neurosci 68:271\u2013274. https:\/\/doi.org\/10.1016\/j.jocn.2019.04.028","journal-title":"J Clin Neurosci"},{"key":"5732_CR13","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s11060-020-03428-5","volume":"147","author":"R Raj","year":"2020","unstructured":"Raj R, Sepp\u00e4 K, Luostarinen T, Malila N, Sepp\u00e4l\u00e4 M, Pitk\u00e4niemi J et al (2020) Disparities in glioblastoma survival by case volume: a nationwide observational study. J Neurooncol 147:361\u2013370. https:\/\/doi.org\/10.1007\/s11060-020-03428-5","journal-title":"J Neurooncol"},{"key":"5732_CR14","doi-asserted-by":"publisher","unstructured":"Flanagan BE, Gregory EW, Hallisey EJ, Heitgerd JL, Lewis B (2011) A social vulnerability index for disaster management. J Homel Secur Emerg Manag 8. https:\/\/doi.org\/10.2202\/1547-7355.1792","DOI":"10.2202\/1547-7355.1792"},{"key":"5732_CR15","unstructured":"Centers for Disease Control and Prevention\/Agency for Toxic Substances and Disease Registry\/Geospatial Research, Analysis, and Services Program (2022) CDC\/ATSDR Social Vulnerability Index 2022 Database: Texas. https:\/\/www.atsdr.cdc.gov\/place-health\/php\/svi\/svi-data-documentation-download.html. Accessed 28 May 2026"},{"key":"5732_CR16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10552-023-01683-1","volume":"34","author":"T Tran","year":"2023","unstructured":"Tran T, Rousseau MA, Farris DP, Bauer C, Nelson KC, Doan HQ (2023) The social vulnerability index as a risk stratification tool for health disparity research in cancer patients: a scoping review. Cancer Causes Control 34:407\u2013420. https:\/\/doi.org\/10.1007\/s10552-023-01683-1","journal-title":"Cancer Causes Control"},{"key":"5732_CR17","doi-asserted-by":"publisher","first-page":"1422475","DOI":"10.3389\/fonc.2024.1422475","volume":"14","author":"A Mehta","year":"2024","unstructured":"Mehta A, Jeon WJ, Nagaraj G (2024) Association of US county-level social vulnerability index with breast, colorectal, and lung cancer screening, incidence, and mortality rates across US counties. Front Oncol 14:1422475. https:\/\/doi.org\/10.3389\/fonc.2024.1422475","journal-title":"Front Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05732-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05732-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05732-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:27:07Z","timestamp":1788247627000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05732-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5732"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05732-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9865692\/v1","asserted-by":"object"}]},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"30 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of The University of Texas MD Anderson Cancer Center and was conducted in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants included in the study provided PROACTIVE consent for research use of their clinical data.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ernest Hawk reports institutional research support from the National Cancer Institute, Cancer Prevention and Research Institute of Texas, Exact Sciences, and the Boone Pickens Distinguished Chair for Early Prevention of Cancer; honoraria for external scientific advisory board service from multiple cancer centers; board service for CATCH Global Foundation; honoraria from AACR; and travel support from DKFZ and the National Cancer Institute. All other authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"21"}}